Semaglutide, when combined with automated insulin delivery, increased the proportion of adults with type 1 diabetes and obesity achieving optimal glucose control and at least 5% weight loss.
36% of patients on semaglutide met the composite endpoint versus 0% on placebo.
Improvements were observed in time-in-range, HbA1c, and body weight, without increased risk of severe hypoglycemia or diabetic ketoacidosis.
